Teva Reports Second Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Wall Street ends down as US-Iran peace optimism fades
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Teva Pharma (TEVA) Grinds Lower, Shares Down Another 9%
August 7, 2017 2:58 PM EDTTeva Pharma (NYSE: TEVA) Grinds Lower, Shares Down Another 9%
... MoreTeva Pharma (TEVA) Lowers Quarterly Dividend 75% to $0.085; 1.1% Yield
August 3, 2017 6:35 AM EDTTeva Pharma (NYSE: TEVA) declared a quarterly dividend of $0.085 per share, or $0.34 annualized. This is a 75% decrease from the prior dividend of $0.34.
The dividend will be payable on September 14, 2017, to stockholders of record on August 29, 2017, with an ex-dividend date of August 25,... More
Teva Pharma (TEVA) Misses Q2 EPS by 4c, Lowers FY EPS Guidance, Cuts Dividend
August 3, 2017 6:33 AM EDT(Updated - August 3, 2017 6:40 AM EDT)
Teva Pharma (NYSE: TEVA) reported Q2 EPS of $1.02, $0.04 worse than the analyst estimate of $1.06. Revenue for the quarter came in at $5.7 billion versus the consensus estimate of $5.76 billion.
GUIDANCE:
Teva Pharma sees Q3 2017 EPS of $4.30-$4.50, versus the consensus of $4.74.
We... More